Introduction {#Sec1}
============

The introduction of GLP-1 receptor agonists (GLP-1 RA) has brought an attractive treatment addition to the therapeutic armamentarium for type 2 diabetes (T2DM), being the first generation of antidiabetic drugs with a significant positive effect on weight and without evidence for increased risk of hypoglycemia. Although the incretin effect was first reported in the 1980s, it took more than two decades until the first GLP-1 RA was developed for therapeutic use in 2005 \[[@CR1], [@CR2]\]. Nowadays, the significance of this drug class has become indisputable and is reflected in the current position statement of the American Diabetes Association/European Association for the Study of Diabetes, where its use is recommended in nearly all stages of the disease \[[@CR3]\]. Owing to the beneficial findings in some of the recent cardiovascular outcome trials \[[@CR4]\], it can be assumed that their use in clinical practice will increase in the future.

While all members of the GLP-1 RA class are united by their activity in tissues carrying GLP-1 receptors---including pancreas, gastrointestinal tract, muscle, heart, brain, kidney, and adipose tissue---a sub-classification of GLP-1 RA based on their pharmacological and clinical properties into short- and long-acting groups seems generally recognized \[[@CR5], [@CR6]\]. The long-acting members like liraglutide, exenatide QW, dulaglutide, albiglutide, or semaglutide continuously act on the GLP-1 receptor which leads to more sustainable reductions of fasting plasma glucose (FPG) and HbA1c when compared to the short-acting class representatives \[[@CR5], [@CR7]\]. At present, exenatide BID and lixisenatide are the only two available drugs within the short-acting group. Their mechanism of action is primarily deceleration of the gastric emptying, which leads to the reduction of postprandial glucose (PPG) excursions \[[@CR6], [@CR8]\] and thereby reduces post meal insulin expositions \[[@CR9], [@CR10]\].

Lixisenatide became commercially available in Austria in 2014, but ever since its use has been limited exclusively to centers of excellence, including restrictions to a certain subset of patients (e.g., with a body mass index (BMI) greater than 30 and preceding use of DPP-4 inhibitors). The drug has been extensively studied during the pivotal clinical GetGoal program, where its efficacy and safety in combination with oral antidiabetic drugs (OADs) and with basal insulin (BI) have been established \[[@CR11]\]. In addition, the ELIXA outcome trial has confirmed the cardiovascular safety of the drug in a population of patients with recent acute coronary syndrome \[[@CR12]\].

In contrast to randomized clinical trials, real-world studies play a crucial role in evaluating treatment effectiveness, especially in large heterogeneous patient populations, without stringent inclusion and exclusion criteria or other aspects that limit generalizability \[[@CR13], [@CR14]\]. However, only a few reports from real-world studies with lixisenatide have emerged recently \[[@CR15]--[@CR17]\]. Therefore we conducted an observational study called PATIO (Prandial Adding Therapy to Insulin or OAD) in order to better understand the efficacy and safety of the drug under real-life conditions, specifically under the terms of the reimbursement rules of this drug in Austria and to evaluate whether the study results reflect those previously observed in large randomized clinical trials.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

PATIO was a prospective, open-label, observational, multicenter study in Austria conducted in patients with type 2 diabetes treated in an outpatients setting. As required by the Austrian Medicines Act, this type of observational study allows only for documentation of data according to clinical practice and within the drug label. Moreover participating centers neither received specific instructions from any party nor conducted additional diagnostic or therapeutic interventions, besides those that were performed routinely anyway. The study protocol was approved by local ethic committees as applicable and the Austrian Ministry of Health was notified of study conduct (registration number NIS004164; <https://forms.ages.at/nis/listNis.do>). This study was reviewed and approved under protocol EK 14--247-VK-NIS by the Ethic Committee of the City of Vienna, protocol EK Nr. 1072/2015 by the Medical University of Vienna, EK-Votum 02/2014 by the Austrian Working Group for Clinical Pharmacology and Therapy and was performed in accordance with the ethical standards of the 1964 Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study.

Data Collection and Management {#Sec4}
------------------------------

The selection of centers aimed to ensure equal geographic distribution as well as representation of office-based and clinic specialists as well as academic and non-academic institutions. Participating physicians received case report forms (CRF) and training in reporting of adverse events (AEs) by the study sponsor. Data collection was performed during routine visits in a paper-based form. The patients were identified on the documentation sheets by means of code (pseudonymized data collection). The type of the collected patient data included demographics, history of the disease, glycemic and lipid parameters, timing of injection, concomitant antidiabetic medication, and safety data with special focus on hypoglycemic events and gastrointestinal disorders.

Patient Population and Study Medication {#Sec5}
---------------------------------------

The aim of the study was to evaluate the efficacy, safety, and tolerability of lixisenatide with respect to the use of the drug either in combination with OADs alone or with basal insulin. Patients were eligible for study after they have signed informed consent and fulfilled the following criteria: type 2 diabetes, age of 18 or older, HbA1c greater than 7.0%, history of use of DPP-4 inhibitors in the highest tolerated dose for at least 3 months and/or use of basal insulin for at least 3 months (according to the Austrian reimbursement rules, all patients had to have one of the five DPP-4 inhibitors registered in Austria before intensifying to a GLP-1 RA, i.e., sitagliptin, vildagliptin, saxagliptin, alogliptin, or linagliptin), BMI greater than 30 kg/m^2^, GLP-1 RA naïve, and able to conduct self-measured plasma glucose (SMPG) monitoring. On the other hand, patients were ineligible if their treatment regimen continued or planned to include DPP-4 inhibitors, sulfonylureas, glinides, if they had or there was a plan to establish a mealtime insulin or if they had reduced renal function (estimated glomerular filtration rate below 45 ml/min), history of acute or chronic pancreatitis, severe gastrointestinal disease, diagnosis of cancer within the last 5 years (or pancreas carcinoma at any time), or any other life-threatening disease. Patients were asked to provide documentation on glucose levels either in a 4- or 7-point SMBG profile. Measurements were carried out by patients' own glucometer devices. Confirmed and confirmed nocturnal symptomatic hypoglycemic events were defined as blood glucose concentrations of 70 mg/dl or less. Severe hypoglycemia was defined as an episode in which a patient required help from another person and addition of glucose was required or a measured blood glucose concentration of 54 mg/dl or less was indicated.

Lixisenatide (Lyxumia®, sanofi-aventis groupe, Paris) was given subcutaneously once daily 60 min before the main meal with the starting dose of 10 μg in the first 14 days and then increased to 20 μg after that. The therapy was documented for up to approximately 6 months. The three study visits were scheduled for baseline, then approximately 2 (week 6--10) and 6 months (week 22--30) after the study began.

Study Outcomes {#Sec6}
==============

The primary outcome parameter of the study was change of HbA1c in the total population as well as in both subpopulations of interest (basal insulin and OADs) from baseline to visit 3. The secondary outcome parameters included change in fasting and postprandial glucose after lixisenatide administration, the response rate (patients with HbA1c below 7.0%, or achieving their individual target value defined by the investigator, or achieving a combined endpoint defined by HbA1c below 7.0%, no occurrence of hypoglycemic events, and no weight gain), change of weight, waist circumference, and BMI at all visits, use and type of OADs and BI at baseline and at the end of the study, occurrence of hypoglycemic events and gastrointestinal adverse effects, including early withdrawals due to adverse effects.

Statistical Considerations {#Sec7}
--------------------------

PATIO was an observational, open-label study without comparator arm. The study was descriptive in nature and did not involve the testing of any pre-formulated hypotheses. Thus, no formal calculation of statistical power was carried out. Nonetheless the following statistical precision could have been achieved for the mean reduction in the HbA1c value (measured in percent): for a sample size of 300 patients, assuming a standard deviation of 1.1%, the length of the two-sided 95% confidence interval for the mean decrease was 0.25%; in a subgroup of 150 patients the length of the 95% confidence interval was 0.35%. For an assumed hypoglycemia rate of 25%, the length of a two-sided 95% confidence interval was 10.1% for 300 and 14.2% for 150 patients, respectively. A lower hypoglycemia rate of 15.0% would translate into 8.2% for 300 and 11.8% for 150 patients.

Results {#Sec8}
=======

Between September 2014 and December 2016 a total of 144 patients were enrolled in the study in 23 centers. Of those, 138 patients were documented during visit 2, carried out on average 57 days after visit 1, and 113 were followed up until visit 3, which was carried out on average 174 days after visit 1. The most frequently used oral drug at the study entry was metformin (73.6%) and 41.7% of the patients received basal insulin. Of those, the majority of 37 patients (61.7%) used human NPH insulin and 23 (38.3%) used long-acting insulin analogues. Basal insulin treatment was ongoing and documented in 48 patients (42.5%) at visit 3. The total insulin dose showed a moderate decrease from 29.4 to 27.9 units throughout the study.

A BMI greater than 30 kg/m^2^ was noticed in 139 (97.2%) patients. The mean weight was 117 ± 18 kg in men and 101 ± 16 kg in women. At baseline, the mean disease duration was 11 ± 7 years in men and 14 ± 9 years in women. The individually defined HbA1c target values were 7.1% ± 0.5. Baseline characteristics of the patients are presented in Table [1](#Tab1){ref-type="table"}.Table 1Baseline characteristics of the patientsMean (SD)OAD group (*n* = 84)Basal insulin group (*n* = 60)Total (*n* = 144)Age, years58.3 (9)64.0 (10)60.7 (9.8)Female sex, *n* (%)34 (40)40 (67)51.4 (74)Weight, kg109.7 (20.6)100.9 (17.2)106 (19.7)BMI, kg/m^2^37.0 (5.6)35.5 (5.1)36.4 (5.4)Waist circumference121.3 (14.6)119.2 (13.4)120.4 (14.1)Disease duration, years10.3 (5.9)15.4 (9.9)12.4 (8.1)Duration of insulin therapy4.9 (6.1)HbA1c8.9 (2.4)8.5 (1.4)8.7 (2.0)FPG (mg/dl)190.4 (53.0)169.4 (55.1)181.8 (54.7)PPG (mg/dl)215.4 (59.2)230 (68.4)221.9 (63.4)Triglycerides208.4 (105.5)178.3 (101.2)196.1 (104.5)HDL cholesterol45.4 (11.6)47.7 (12.6)46.3 (12)LDL cholesterol96.4 (42.9)91.5 (33.8)94.4 (38.5)Total cholesterol176.5 (42.6)171.9 (42)174.6 (42.3)

After lixisenatide was prescribed independently of the study, patients could be enrolled. A total of 93 patients (65%) continued lixisenatide until the end of the study. In 43 patients (30%), discontinuation was reported on average after 125 ± 68 days. The main reasons for discontinuation included lacking effectiveness (19 cases, 13.2%) and adverse events (9 cases, 6.3%). In patients who received insulin, the drug had been applied for 4.9 ± 6.1 years. At all visits, lixisenatide was injected before breakfast in 61%, lunch in 19%, and dinner 21% of the cases.

Furthermore, all patients received concomitant medication during the study. Most medications were classified as ATC-C (cardiovascular medications, 101 prescriptions) and ATC-A (alimentary tract and metabolism, 89 prescriptions). However, besides diabetes therapies, concomitant medication was collected only in case of AEs, thus allowing for incomplete recording.

Effectiveness {#Sec9}
-------------

Among patients who completed the study the following changes were observed from baseline to month 6 (Fig. [1](#Fig1){ref-type="fig"}).

Fig. 1Patients flow diagram in the study

Average HbA1c in the 112 patients who completed all three study visits declined by 0.7 ± 1.6%; *p* \< 0.0001 (for total population from 8.7% (72 mmol/mol) to 7.9% (63 mmol/mol), Fig. [2](#Fig2){ref-type="fig"}). The proportion of patients participating in visit 3 who achieved HbA1c below 7.0% was 24.8% (*n* = 28). Patients with BI showed slightly higher response rates (27.1%) than OAD patients (23.1%); *p* = 0.664 between groups. The combined endpoint of HbA1c below 7.0% (53 mmol/mol), with no weight gain, and no hypoglycemia was achieved by 18.1% of all patients and 22.9% of the patients participating in visit 3. More patients with a disease duration of up to 10 years achieved HbA1c below 7.0% and the combined endpoint when compared to patients with a disease history of more than 10 years (32.7% vs. 19.2% and 29.1% vs. 19.2%).Fig. 2Change in HbA1c and weight during the study

Fasting and postprandial blood glucose dropped on average by 27 ± 58 mg/dl (*p* \< 0.0001) and 45 ± 67 mg/dl (*p* \< 0.0001), respectively (for changes in total population, see Fig. [3](#Fig3){ref-type="fig"}; for 7-point SMBG profiles, see Fig. [4](#Fig4){ref-type="fig"}). The median daily swings (peak--trough) of glucose concentrations were also diminished by 26 ± 46 (*p* \< 0.0001; from 103 ± 51 mg/dl at visit 1 to 78 ± 42 mg/dl at visit 3).Fig. 3Change in fasting plasma glucose (FPG) and postprandial plasma glucose (PPG) during the study Fig. 4Mean 7-point SMBG profiles from visit 3 to visit 5

Body weight decreased throughout the study by 4.5 ± 5.4 kg (*p* \< 0.0001). In the BI group, the decrease was 4.0 ± 5.3 kg and in the OAD group the decrease was 4.9 ± 5.5 kg; *p* \< 0.0001 respectively and *p* = 0.386 between groups, without gender-specific differences (for changes in total population, see Fig. [2](#Fig2){ref-type="fig"}). The number of obese patients (BMI 30 kg/m^2^ or higher) dropped from 97% (total population) to 83% in the BI group and from 98% to 88% in the OAD group. Waist circumference was reduced by 3.6 ± 4.7 cm (*p* \< 0.0001), with small differences between genders or treatment groups.

Systolic blood pressure decreased by 4.8 ± 17.1 mmHg (*p* = 0.0066; for total population from 140.5 ± 18 to 135 ± 16 mmHg). A numerically smaller reduction of 2.3 ± 10.6 mmHg (*p* = 0.0342) was reported for diastolic blood pressure (for total population from 83 ± 11 to 81 ± 9 mmHg).

With respect to laboratory parameters, patients showed a decrease in triglycerides by 10.8 ± 105.4 mg/dl (*p* = 0.3504). The reduction appeared stronger in women (− 18.7 ± 126.4 mg/dl; *p* = 0.3552) than in men (− 3.5 ± 82.6 mg/dl; *p* = 0.78); *p* = 0.51 between gender groups. HDL cholesterol remained nearly constant with a slight increase of approximately 1.2 ± 9.2 mg/dl (*p* = 0.2353). LDL cholesterol, on the other hand, was reduced by 3.7 ± 25.2 mg/dl (*p* = 0.2045). Interestingly, in women a decrease of 9.7 ± 28.7 mg/dl (*p* = 0.0536) was observed compared to men, where even a slight increase of 1.4 ± 20.9 mg/dl (*p* = 0.67) was found (*p* = 0.0555 between gender groups). This was also true for total cholesterol, where the decrease was predominantly observed in the female patients (− 5.7 ± 44.7 mg/dl; *p* = 0.4249), and virtually no change was found in male patients (0.1 ± 24.6 mg/l; *p* = 0.98); *p* = 0.458 between gender groups.

Safety Parameters {#Sec10}
-----------------

AEs were generally rare with a total of 77 events that affected 48 patients. Most frequently, patients experienced gastrointestinal disorders (27 patients, 18.8%), followed by general disorders and administration site conditions (9 patients, 6.3%). All other classes of adverse events affected less than 5% of the patients. Two events resulted in hospitalization and were classified as serious, one due to an accident resulting in rib fracture, and one involving syncope and vomiting. Only the latter was assessed as related to the study medication. Overall, a causal relationship to the medication was excluded for 13 AEs (16.9%). The majority of AEs (50 events, 64%) were classified as "mild", 22 events (28.6%) were assessed as "moderate", and 5 (6.5%) as "severe". The actions taken with regard to the study medication involved no change (37 AEs, 48.1%) and withdrawal (33 cases, 42.9%).

Gastrointestinal discomfort was reported by 7 patients (4.9%) at visit 1, by 23 (16.8%) at visit 2, and by 5 patients (4.4%) at visit 3 (Fig. [5](#Fig5){ref-type="fig"}). Throughout the study, men were more affected than women. The most abundant symptom of gastrointestinal discomfort was nausea, followed by vomiting and diarrhea. No case of pancreatitis was reported during the study.Fig. 5Gastrointestinal disturbances reported at visit 2 and visit 3

A small proportion of patients were affected by hypoglycemic events, which were recorded in 5 patients (3.5%) prior to visit 1, in 3 patients (2.2%) at visit 2, and not at all at visit 3. Only one hypoglycemic event between visit 1 and 2 occurred at night, and one event prior to visit 1 was severe. No severe nocturnal hypoglycemia events were reported. Hypoglycemic events appeared to be more frequent in patients treated with OADs; however, the number of events was too low for a meaningful analysis.

Discussion {#Sec11}
==========

The magnitude of effects of a drug in regular clinical practice potentially may differ from those reported in randomized clinical trials \[[@CR18]\]. In this context, however, our study has confirmed the already well-defined clinical profile of lixisenatide. At the end of our study, 24.8% of patients receiving therapy achieved HbA1c levels below 7.0%, which echoes the response rates seen in the intention-to-treat (ITT) analysis of the GetGoal program with lixisenatide, but exceeds the ones recently reported in a real-life study, where lixisenatide was compared with liraglutide \[[@CR16]\]. Whereas the higher percentage of patients reaching an HbA1c goal below 7% can be explained by the lower baseline HbA1c level in our study \[8.7% (72 mmol/mol) vs. 9.5% (80 mmol/mol)\], it is noteworthy that the reduction of HbA1c of about 0.7% is comparable in both studies, despite the lower HbA1c in this study. Of note, all patients in our study had a pre-treatment with a DPP-4 inhibitor, which was stopped at the initiation of lixisenatide, underscoring the effectiveness of lixisenatide even after use of oral incretins. Positive influences of lixisenatide on blood lipids and blood pressure were also in line with previous findings. Note that the observed mean weight loss of 4 kg in our real-life setting was stronger than in the GetGoal studies \[[@CR11]\], possibly because of a higher BMI at baseline as well as analyses of patients who completed the treatment.

In terms of patient population, more than half of the patients in PATIO were not on basal insulin yet, although average HbA1c before study entry was 8.9% (74 mmol/mol). This finding overlaps with results from a previous multinational study \[[@CR19]\] and indicates a significant clinical inertia towards start of insulin therapy in general. Of note, patients already treated with basal insulin were also far away from their anticipated HbA1c goals, despite being on insulin treatment for nearly 5 years. Different reasons, not necessarily related to the type of insulin used, might have contributed to that fact. Firstly, study patients were receiving rather moderate doses of 29 units/day. Given the high BMI in studied patients of above 35 kg/m^2^, it is doubtful that the chosen insulin dose was sufficient to control glycemia. Secondly, FPG levels at study entry were around 180 mg/dl and although moderately reduced during the study (156.3 mg/dl and 146.3 mg/dl for the second and the third study visit), they remained above the recommended target of 130 mg/dl \[[@CR20]\]. The latter finding also suggests a lack of the treat-to-target approach in the cases documented in our study. One can speculate whether the study investigators were aware of the intrinsic moderate impact of lixisenatide on the FPG and the need for basal insulin dose adaptation following lixisenatide initiation. Finally, nearly two thirds of the patients in our cohort used NPH insulin. This high percentage of use of human basal insulin is different from the patient populations in multinational studies conducted with lixisenatide in combination with insulin glargine. This difference arises because the Austrian health insurance system only reimburses human insulin for the first-line basal insulin therapy. The costs for long-acting insulin analogues are covered only in the case of recurrent night-time episodes of hypoglycemia by the therapy with NPH insulin. The large use of NPH in addition to the clinical inertia to increase basal insulin doses may explain why patients were not at FPG target during the study.

In light of some earlier research, it could be assumed that the effect on prandial control becomes generally more "visible" with lower HbA1c values \[[@CR21], [@CR22]\]. In the present study average postprandial blood glucose after lixisenatide administration was reduced from 222 mg/dl at visit 1 to 172 mg/dl at visit 3, meeting the target for postprandial glucose of below 180 mg/dl, defined by the ADA \[[@CR23]\]. Given the mechanism of action of lixisenatide, the combination with basal insulin pursues complementary targets and appears to be a very logical treatment approach. The concept of basal and prandial control in the context of lixisenatide has already been proven therapeutically successful in several randomized clinical trials of either combination of free components \[[@CR24]--[@CR26]\] or fixed-ratio combination \[[@CR27], [@CR28]\]. However, those were large interventional studies and followed the typical treat-to-target formula, which was not applied in our study.

The relatively high discontinuation rate in our study of 30% (43 patients) had multiple causes; however, the one most commonly reported reason was "lack of efficacy" in a total of 21 cases. In this context it needs to be mentioned that the study protocol has not clearly predefined that term, but left it to the discretion of the investigator as a result of the observational nature of our study. Also, as defined by the legal framework in Austria, the supply of study medication by the sponsor was not permitted for observational studies. Thereby physicians had to provide details of the clinical status for every single treatment course after a few weeks of initial treatment with lixisenatide in written form and apply for reimbursement to the health insurance provider and this administrative workload may have limited the lixisenatide treatment refill. Only seven patients reported a discontinuation due to adverse events. Other reasons included the patients' wishes \[[@CR15]\], no reimbursement of the drug \[[@CR11]\], and scheduled surgery \[[@CR3]\].

Our study has several limitations including its open-label character, lack of comparator arm, relatively small total number of patients included who completed the evaluation, and finally the quite heterogeneous population as a part of the effort to reflect clinical reality. The participants in the study tend to have higher BMIs than the general population and selected centers were perhaps more experienced in conducting studies than the rest of the physicians in the country, thereby shrinking the generalizability of the results to the entire population. Furthermore, subgroups in our study were too small to clearly identify trends or differences in response, so larger studies will be needed to follow any hypotheses potentially originating from PATIO. The very few reported episodes of hypoglycemia, which probably reflected the generally high HbA1c levels of patients enrolled, the relatively low dose of basal insulin, and exclusion of patients with sulfonylureas or glinides. However, the events could also be underreported, a common issue in real-life studies.

Conclusion {#Sec12}
==========

Lixisenatide showed in our study a similar efficacy and safety profile under real-life conditions as already demonstrated in randomized clinical trials. Educational efforts towards identifying appropriate patients with the need for postprandial glucose control have potential to further improve outcomes with lixisenatide in routine clinical practice.
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